TY - JOUR
T1 - Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal β2-agonist
AU - Akamatsu, K.
AU - Yamagata, T.
AU - Takahashi, T.
AU - Miura, K.
AU - Maeda, S.
AU - Yamagata, Y.
AU - Ichikawa, T.
AU - Yanagisawa, S.
AU - Ueshima, K.
AU - Hirano, T.
AU - Nakanishi, M.
AU - Matsunaga, K.
AU - Minakata, Y.
AU - Ichinose, M.
N1 - Funding Information:
We thank Mr. Brent Bell for reading the manuscript. This study was supported by Nippon Boehringer Ingelheim Co., Ltd.
PY - 2007/12
Y1 - 2007/12
N2 - Background: A combination of bronchodilators may be effective in the treatment of chronic obstructive pulmonary disease (COPD). We examined the effect of adding a long-acting anti-cholinergic agent (tiotropium) to a transdermal-type β2-agonist (tulobuterol) on dyspnea as well as pulmonary function. Methods: In a multicentre, randomized, parallel design study, 60 COPD patients treated with the transdermal β2-agonist tulobuterol were divided into a tiotropium added group (Tulo+Tio group, n = 40) or transdermal β2-agonist tulobuterol alone group (Tulo group, n = 20), and then treated for 4 weeks after a 2 week run-in period. Pulmonary function and a dyspnea (Medical Research Council (MRC)) scale were assessed before and after the treatment. Daily peak expiratory flow (PEF) monitoring was also performed. Results: After 4 weeks, the Tulo+Tio group showed a significant increase in pulmonary function compared with the Tulo group; ΔFVC (0.31±0.06 L vs. 0.06±0.05 L, p< 0.01), ΔFEV1 (0.15±0.03 L vs. -0.02±0.02 L, p<0.0001), and ΔPEF (41.0±5.1 L/min vs. 0.5±3.5 L/min, p<0.0001). The MRC dyspnea scale was also significantly improved in Tulo+Tio, but not in Tulo group. Conclusion: These results suggest that tiotropium caused a significant improvement in both pulmonary function and dyspnea in COPD patients already treated with the transdermal β2-agonist tulobuterol.
AB - Background: A combination of bronchodilators may be effective in the treatment of chronic obstructive pulmonary disease (COPD). We examined the effect of adding a long-acting anti-cholinergic agent (tiotropium) to a transdermal-type β2-agonist (tulobuterol) on dyspnea as well as pulmonary function. Methods: In a multicentre, randomized, parallel design study, 60 COPD patients treated with the transdermal β2-agonist tulobuterol were divided into a tiotropium added group (Tulo+Tio group, n = 40) or transdermal β2-agonist tulobuterol alone group (Tulo group, n = 20), and then treated for 4 weeks after a 2 week run-in period. Pulmonary function and a dyspnea (Medical Research Council (MRC)) scale were assessed before and after the treatment. Daily peak expiratory flow (PEF) monitoring was also performed. Results: After 4 weeks, the Tulo+Tio group showed a significant increase in pulmonary function compared with the Tulo group; ΔFVC (0.31±0.06 L vs. 0.06±0.05 L, p< 0.01), ΔFEV1 (0.15±0.03 L vs. -0.02±0.02 L, p<0.0001), and ΔPEF (41.0±5.1 L/min vs. 0.5±3.5 L/min, p<0.0001). The MRC dyspnea scale was also significantly improved in Tulo+Tio, but not in Tulo group. Conclusion: These results suggest that tiotropium caused a significant improvement in both pulmonary function and dyspnea in COPD patients already treated with the transdermal β2-agonist tulobuterol.
KW - Combination therapy
KW - Dyspnea
KW - Pulmonary function
KW - Tiotropium
KW - Transdermal β-agonist tulobuterol
UR - http://www.scopus.com/inward/record.url?scp=34548826226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548826226&partnerID=8YFLogxK
U2 - 10.1016/j.pupt.2006.08.004
DO - 10.1016/j.pupt.2006.08.004
M3 - Article
C2 - 17049894
AN - SCOPUS:34548826226
SN - 1094-5539
VL - 20
SP - 701
EP - 707
JO - Pulmonary Pharmacology and Therapeutics
JF - Pulmonary Pharmacology and Therapeutics
IS - 6
ER -